Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2017 53 154 M
EBIT 2017 18 423 M
Net income 2017 11 484 M
Debt 2017 8 962 M
Yield 2017 3,39%
Sales 2018 56 090 M
EBIT 2018 19 764 M
Net income 2018 12 985 M
Debt 2018 2 941 M
Yield 2018 3,60%
P/E ratio 2017 18,76
P/E ratio 2018 17,11
EV / Sales2017 4,30x
EV / Sales2018 3,97x
Capitalization 219 544 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
03/29Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
03/29 ROCHE : FDA Advisory Committee Unanimously Recommends Approval of Genentech&rsqu..
03/29 ROCHE : FDA Approves Genentech's OCREVUS (Ocrelizumab) For Relapsing and Primary..
03/29 ROCHE : FDA approves Roche's OCREVUS™ (ocrelizumab) for relapsing and prim..
03/29 ROCHE : FDA approves Roche’s OCREVUS™ (ocrelizumab) for relapsing an..
03/29 ROCHE : FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) for Relapsin..
03/28 ROCHE : announces launch of cobas HPV on the cobas 6800/8800 Systems for cervica..
03/28 ROCHE : Addressing Threat Of Zika Virus To US Blood Supply
03/27 ROCHE : Health and Human Services Department (HHS); Food and Drug Administration..
03/27 Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/27 ROCHE : Dying patients want easier access to experimental drugs
More news
Sector news : Pharmaceuticals - NEC
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
03/28DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 281  CHF
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.221 256
JOHNSON & JOHNSON9.07%340 651
ROCHE HOLDING LTD.8.81%221 256
PFIZER INC.5.70%203 427
NOVARTIS AG-0.47%196 620
MERCK & CO., INC.8.10%173 904
More Results